Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

miR-22 suppresses DNA ligase III addiction in multiple myeloma.

Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P.

Leukemia. 2018 Aug 17. doi: 10.1038/s41375-018-0238-2. [Epub ahead of print]

PMID:
30120376
2.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-mir-17-92.

Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P.

Blood. 2018 Jul 11. pii: blood-2018-03-836601. doi: 10.1182/blood-2018-03-836601. [Epub ahead of print]

PMID:
29997223
3.

Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation.

Raimondi L, De Luca A, Giavaresi G, Barone A, Tagliaferri P, Tassone P, Amodio N.

Curr Med Chem. 2018 Jun 29. doi: 10.2174/0929867325666180629153141. [Epub ahead of print]

PMID:
29956610
4.

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.

Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG, Tagliaferri P.

Oncotarget. 2018 Apr 17;9(29):20539-20554. doi: 10.18632/oncotarget.24993. eCollection 2018 Apr 17.

5.

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches.

Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P.

J Hematol Oncol. 2018 May 8;11(1):63. doi: 10.1186/s13045-018-0606-4. Review.

6.

Mouse models of multiple myeloma: technologic platforms and perspectives.

Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P.

Oncotarget. 2018 Apr 13;9(28):20119-20133. doi: 10.18632/oncotarget.24614. eCollection 2018 Apr 13. Review.

7.

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.

Santolla MF, Lappano R, Cirillo F, Rigiracciolo DC, Sebastiani A, Abonante S, Tassone P, Tagliaferri P, Di Martino MT, Maggiolini M, Vivacqua A.

J Exp Clin Cancer Res. 2018 May 2;37(1):94. doi: 10.1186/s13046-018-0767-6.

8.

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.

Ciliberto D, Staropoli N, Caglioti F, Chiellino S, Ierardi A, Ingargiola R, Botta C, Arbitrio M, Correale P, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 May;125:69-77. doi: 10.1016/j.critrevonc.2018.03.003. Epub 2018 Mar 9. Review.

PMID:
29650279
9.

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.

Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Feb 22. doi: 10.1038/s41375-018-0067-3. [Epub ahead of print]

10.

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.

Botta C, Ciliberto D, Rossi M, Staropoli N, Cucè M, Galeano T, Tagliaferri P, Tassone P.

Blood Adv. 2017 Feb 27;1(7):455-466. doi: 10.1182/bloodadvances.2016003905. eCollection 2017 Feb 28.

11.

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.

Stamato MA, Juli G, Romeo E, Ronchetti D, Arbitrio M, Caracciolo D, Neri A, Tagliaferri P, Tassone P, Amodio N.

Oncotarget. 2017 Nov 20;8(63):106527-106537. doi: 10.18632/oncotarget.22507. eCollection 2017 Dec 5.

12.

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.

Zarone MR, Misso G, Grimaldi A, Zappavigna S, Russo M, Amler E, Di Martino MT, Amodio N, Tagliaferri P, Tassone P, Caraglia M.

Sci Rep. 2017 Dec 20;7(1):17949. doi: 10.1038/s41598-017-18186-0.

13.

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.

Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, Botta C, Zarone MR, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, Tassone P, Tagliaferri P, Cusi MG, Pirtoli L, Correale P.

J Thorac Dis. 2017 Sep;9(9):3123-3131. doi: 10.21037/jtd.2017.08.68.

14.

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.

Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC.

Leukemia. 2018 Apr;32(4):996-1002. doi: 10.1038/leu.2017.334. Epub 2017 Nov 21.

15.

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.

Botta C, Cucè M, Pitari MR, Caracciolo D, Gullà A, Morelli E, Riillo C, Biamonte L, Gallo Cantafio ME, Prabhala R, Mignogna C, Di Vito A, Altomare E, Amodio N, Di Martino MT, Correale P, Rossi M, Giordano A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Apr;32(4):1003-1015. doi: 10.1038/leu.2017.336. Epub 2017 Nov 21.

16.

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P.

Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29.

17.

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.

de Castro J, Tagliaferri P, de Lima VCC, Ng S, Thomas M, Arunachalam A, Cao X, Kothari S, Burke T, Myeong H, Grattan A, Lee DH.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12734. Epub 2017 Jul 27.

18.

Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

Botta C, Cuce M, Caracciolo D, Fiorillo L, Tagliaferri P, Tassone P.

Curr Cancer Drug Targets. 2017;17(9):819-838. doi: 10.2174/1568009617666170330154756. Review.

PMID:
28359248
19.

Immunotherapy of colorectal cancer: new perspectives after a long path.

Correale P, Botta C, Ciliberto D, Pastina P, Ingargiola R, Zappavigna S, Tassone P, Pirtoli L, Caraglia M, Tagliaferri P.

Immunotherapy. 2016 Nov;8(11):1281-1292. Review.

PMID:
27993089
20.

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.

Botta C, Di Martino MT, Ciliberto D, Cucè M, Correale P, Rossi M, Tagliaferri P, Tassone P.

Blood Cancer J. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118.

21.

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.

Nardone V, Botta C, Caraglia M, Martino EC, Ambrosio MR, Carfagno T, Tini P, Semeraro L, Misso G, Grimaldi A, Boccellino M, Facchini G, Berretta M, Vischi G, Rocca BJ, Barone A, Tassone P, Tagliaferri P, Del Vecchio MT, Pirtoli L, Correale P.

Cancer Biol Ther. 2016 Nov;17(11):1213-1220.

22.

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation.

Staropoli N, Ciliberto D, Chiellino S, Caglioti F, Giudice TD, Gualtieri S, Salvino A, Strangio A, Botta C, Pignata S, Tassone P, Tagliaferri P.

Oncotarget. 2016 Dec 13;7(50):82741-82756. doi: 10.18632/oncotarget.12633. Review.

23.

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.

Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, Tassone P, Ulivieri C, Tagliaferri P, Cusi MG, Caraglia M, Correale P.

Cell Death Discov. 2016 Oct 3;2:16025. eCollection 2016.

24.

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes.

Agapito G, Botta C, Guzzi PH, Arbitrio M, Di Martino MT, Tassone P, Tagliaferri P, Cannataro M.

Microarrays (Basel). 2016 Sep 23;5(4). pii: E24. doi: 10.3390/microarrays5040024.

25.

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response.

Botta C, Misso G, Martino EC, Pirtoli L, Cusi MG, Tassone P, Tagliaferri P, Caraglia M, Correale P.

Cell Death Dis. 2016 Jul 21;7:e2299. doi: 10.1038/cddis.2016.211. No abstract available.

26.

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.

Gallo Cantafio ME, Nielsen BS, Mignogna C, Arbitrio M, Botta C, Frandsen NM, Rolfo C, Tagliaferri P, Tassone P, Di Martino MT.

Mol Ther Nucleic Acids. 2016 Jun 21;5(6). doi: 10.1038/mtna.2016.36.

27.

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.

Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro M, Tassone P, Tagliaferri P.

Oncotarget. 2016 Aug 16;7(33):54028-54050. doi: 10.18632/oncotarget.9927. Review.

28.

Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment.

Misso G, Zarone MR, Grimaldi A, Di Martino MT, Lombardi A, Kawasaki H, Stiuso P, Tassone P, Tagliaferri P, Caraglia M.

Curr Drug Targets. 2017;18(1):35-55. Review.

PMID:
27280795
29.

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.

Pinto C, Bella MA, Capoluongo E, Carrera P, Clemente C, Colombo N, Cortesi L, De Rosa G, Fenizia F, Genuardi M, Gori S, Guarneri V, Marchetti A, Marchetti P, Normanno N, Pasini B, Pignata S, Radice P, Ricevuto E, Russo A, Tagliaferri P, Tassone P, Truini M, Varesco L.

Future Oncol. 2016 Sep;12(18):2071-5. doi: 10.2217/fon-2016-0189. Epub 2016 May 31. Review. No abstract available.

30.

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.

Mignogna C, Staropoli N, Botta C, De Marco C, Rizzuto A, Morelli M, Di Cello A, Franco R, Camastra C, Presta I, Malara N, Salvino A, Tassone P, Tagliaferri P, Barni T, Donato G, Di Vito A.

J Ovarian Res. 2016 May 21;9(1):31. doi: 10.1186/s13048-016-0238-7.

31.

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.

Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P.

Mol Cancer Ther. 2016 Jun;15(6):1364-75. doi: 10.1158/1535-7163.MCT-15-0985. Epub 2016 May 18.

32.

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.

Correale P, Botta C, Martino EC, Ulivieri C, Battaglia G, Carfagno T, Rossetti MG, Fioravanti A, Guidelli GM, Cheleschi S, Gandolfo C, Carbone F, Baldari TC, Tassone P, Tagliaferri P, Pirtoli L, Cusi MG.

Oncoimmunology. 2015 Dec 21;5(4):e1101205. eCollection 2016 Apr.

33.

Mir-221/222 are promising targets for innovative anticancer therapy.

Di Martino MT, Rossi M, Caracciolo D, Gullà A, Tagliaferri P, Tassone P.

Expert Opin Ther Targets. 2016 Sep;20(9):1099-108. doi: 10.1517/14728222.2016.1164693. Epub 2016 Mar 21. Review.

PMID:
26959615
34.

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials.

Rotundo MS, Galeano T, Tassone P, Tagliaferri P.

Oncotarget. 2016 May 10;7(19):27055-66. doi: 10.18632/oncotarget.7446. Review.

35.

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment.

Raimondi L, De Luca A, Morelli E, Giavaresi G, Tagliaferri P, Tassone P, Amodio N.

Biomed Res Int. 2016;2016:6504593. doi: 10.1155/2016/6504593. Epub 2016 Jan 4. Review.

36.

Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer.

Ciliberto D, Staropoli N, Chiellino S, Botta C, Tassone P, Tagliaferri P.

Pancreatology. 2016 Mar-Apr;16(2):249-58. doi: 10.1016/j.pan.2016.01.003. Epub 2016 Jan 20. Review.

PMID:
26852170
37.

MicroRNAs in multiple myeloma and related bone disease.

Rossi M, Tagliaferri P, Tassone P.

Ann Transl Med. 2015 Dec;3(21):334. doi: 10.3978/j.issn.2305-5839.2015.12.13. Review.

38.

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.

Arbitrio M, Di Martino MT, Barbieri V, Agapito G, Guzzi PH, Botta C, Iuliano E, Scionti F, Altomare E, Codispoti S, Conforti S, Cannataro M, Tassone P, Tagliaferri P.

Cancer Chemother Pharmacol. 2016 Jan;77(1):205-9. doi: 10.1007/s00280-015-2916-3. Epub 2015 Nov 25.

PMID:
26607259
39.

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

Gullà A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, Botta C, Pitari MR, Lio SG, Britti D, Stamato MA, Hideshima T, Munshi NC, Anderson KC, Tagliaferri P, Tassone P.

Clin Cancer Res. 2016 Mar 1;22(5):1222-33. doi: 10.1158/1078-0432.CCR-15-0489. Epub 2015 Nov 2.

40.

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.

Pitari MR, Rossi M, Amodio N, Botta C, Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT, Arbitrio M, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2015 Sep 29;6(29):27343-58. doi: 10.18632/oncotarget.4398.

41.

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

Ciliberto D, Staropoli N, Caglioti F, Gualtieri S, Fiorillo L, Chiellino S, De Angelis AM, Mendicino F, Botta C, Caraglia M, Tassone P, Tagliaferri P.

Cancer Biol Ther. 2015;16(8):1148-59. doi: 10.1080/15384047.2015.1056415. Epub 2015 Jun 10.

42.

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma.

Di Martino MT, Guzzi PH, Caracciolo D, Agnelli L, Neri A, Walker BA, Morgan GJ, Cannataro M, Tassone P, Tagliaferri P.

Oncotarget. 2015 Aug 7;6(22):19132-47.

43.

Analysis of miRNA, mRNA, and TF interactions through network-based methods.

Guzzi PH, Di Martino MT, Tagliaferri P, Tassone P, Cannataro M.

EURASIP J Bioinform Syst Biol. 2015 Jun 4;2015:4. doi: 10.1186/s13637-015-0023-8. eCollection 2015 Dec.

44.

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.

Cusi MG, Botta C, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, Basile A, Carbone SF, Ricci V, Micheli L, Tassone P, Tagliaferri P, Pirtoli L, Correale P.

Cancer Immunol Immunother. 2015 Sep;64(9):1159-73. doi: 10.1007/s00262-015-1711-7. Epub 2015 Jun 2.

PMID:
26031574
45.

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.

Morelli E, Leone E, Cantafio ME, Di Martino MT, Amodio N, Biamonte L, Gullà A, Foresta U, Pitari MR, Botta C, Rossi M, Neri A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P.

Leukemia. 2015 Nov;29(11):2173-83. doi: 10.1038/leu.2015.124. Epub 2015 May 19.

46.

Functional Analysis of microRNA in Multiple Myeloma.

Di Martino MT, Amodio N, Tassone P, Tagliaferri P.

Methods Mol Biol. 2016;1375:181-94. doi: 10.1007/7651_2015_250.

PMID:
25971914
47.

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.

Amodio N, Rossi M, Raimondi L, Pitari MR, Botta C, Tagliaferri P, Tassone P.

Oncotarget. 2015 May 30;6(15):12837-61. Review.

48.

Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.

Botta C, Gullà A, Correale P, Tagliaferri P, Tassone P.

Front Oncol. 2014 Dec 8;4:348. doi: 10.3389/fonc.2014.00348. eCollection 2014. Review.

49.

Mir-34: a new weapon against cancer?

Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M.

Mol Ther Nucleic Acids. 2014 Sep 23;3:e194. doi: 10.1038/mtna.2014.47. Review.

50.

MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches.

Rossi M, Amodio N, Di Martino MT, Tagliaferri P, Tassone P, Cho WC.

Curr Pharm Biotechnol. 2014;15(5):459-67. Review.

PMID:
24846067

Supplemental Content

Loading ...
Support Center